Login

Journal Front Page

News & Events

  • Call for article for January 2025 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 4 (October 2024 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION AND EVALUATION OF SELF NANO EMULSIFYING DRUG DELIVERY SYSTEM FOR ANTIHYPERLIPIDEMIC DRUG

Anuja G. Gawai*, Sandip C. Atram, Rupali P. Sable, Vrunda J. Rajput, Subhod A. Urkunde.

Department of pharmaceutics, Vidyabharati College of Pharmacy, Amravati – 444 602, India

ABSTRACT

The aim of this study is to develop an anti-hyperlipidemic, orally soluble atorvastatin. This is a BCS Class II drug. Development of atorvastatin providing improved bioavailability and reduced variability is required. It was prepared by ultrasonic method. The content of the selected drug (SBF4) is 98%, which represent the highest concentration of the drug currently in production. The presence of surfactants and co-surfactants provides greater stability with increased drug release. Development of self-nanoemulsifying drug delivery system (SNEDDS) formulations to improve the solubility and release rate of poorly soluble hypolipidemic drugs. Among the formulations, BF2, BF4 and BF6 showed the highest concentration of 85.10 ± 1.23%, while the commercial formulation showed only 58.49 ± 1.22 cumulative drug release after 90 min. This is the larger drug spread for SNEDDS selection. The aim of the current study is to prepare a stable dose of atorvastatin calcium that improves drug partitioning compared to the existing commercial product (Lipitor 10 mg) and finally differs in oral bioavailability and absorption and reduction in patients. Effects of nutrients on absorption Comparison of drugs with commercial products.

Keywords: BCS, SNEDDS, BF2, BF4, BF6, SBF4


[Full Text Article]